

## Pfizer's Covid paediatric jab needs to win in the home as well as the clinic



[Lisa Urquhart](#)

Pfizer and Biontech today revealed [a 100% efficacy rate for their Covid-19 vaccine](#) in children aged 12 to 15, and hopes of gaining emergency use authorisation by the start of the school year in September. The news is the latest in the race to [get a vaccine into the arms of ever younger individuals](#); Pfizer and [Moderna have announced dose-escalation studies in children](#) aged six months to 11 or 12 years. While impressive, Pfizer's current results are preliminary and in a relatively small sample, so efficacy could wane. There were also few details on adverse events, something that will be keenly watched in children. But perhaps the bigger question with this and all childhood Covid-19 vaccines is uptake, as administration will require parental consent. Young children with Covid-19 tend to be asymptomatic, so concerned parents, who might have already been vaccinated, may not be willing to expose their children to a new vaccine. There of course will be exceptions, like clinically vulnerable children and those who live with the immunocompromised, but with increasing vaccine hesitancy around routine childhood vaccinations Pfizer and other developers might have to work hard to sell this to some parents.

### Commercial studies of Covid-19 vaccines that include paediatrics

Project	Sponsor	Trial	Age	Enrolment
Comirnaty (BNT162b2)	Biontech/Pfizer	<a href="#">NCT04368728</a>	12-adult	43,998
			Extension in 12-15 years	2,260
Comirnaty (BNT162b2)	Biontech/Pfizer	<a href="#">NCT04713553</a>	12-adult	1,530
Comirnaty (BNT162b2)	Biontech/Pfizer	<a href="#">NCT04816643</a>	6 months - 11 years	4,644
mRNA-1273	Moderna/Barda	TeenCove, <a href="#">NCT04649151</a>	12-17 years	3,000
mRNA-1273	Moderna/NIAID/Barda	KidCove, <a href="#">NCT04796896</a>	6 months - 12 years	6,750
Nanocovax	Nanogen	<a href="#">NCT04683484</a>	12-adult	620
SARS-CoV-2 vaccine	Sinovac	<a href="#">NCT04551547</a>	3-7 years	552
Covaxin (BBV152)	Bharat Biotech	<a href="#">NCT04471519</a>	12-adult	755
Vaxzevria (AZD1222)	Astrazeneca/Oxford Uni	<a href="#">COV006</a>	6-17 years	300

Source: Evaluate Pharma & [clinicaltrials.gov](#).

[More from Evaluate Vantage](#)

Evaluate HQ  
[44-\(0\)20-7377-0800](#)

Evaluate Americas  
[+1-617-573-9450](#)

Evaluate APAC  
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2021 Evaluate Ltd.